Article
05 Apr 2024
Class Actions Comparative Guide
AUTHORS CONTENT
Article
30 Sep 2022
Absence Of Evidence Stalls Misleading Advertising Class Action
Article
22 Mar 2021
Health Canada Consults On Proposed Guidelines For The Use Of Electronic Media In Prescription Drug Labelling
Article
16 Jul 2020
Ontario Passes Significant Amendments To Class Proceedings Act
Article
22 Jun 2020
Ontario Lifts Recommendation To Limit Prescription Dispensing To 30 Days' Supply
Article
17 Jun 2020
Arbitrating Disputes In The Pharmaceutical, Life Sciences And Healthcare Sector In The Era Of The COVID-19 Pandemic
Article
24 Apr 2020
Health Canada Releases Guidance Document Addressing The Plain Language Labelling Regulations Requirements For Non-Prescription Drug Products
Article
22 Apr 2020
Health Canada Issues Interim Order To Address Shortages Of Health Products
Article
31 Mar 2020
Ontario And Quebec Introduce Changes To Pharmacy Practice And Highlight The Drug Supply Chain As An Essential Service
Article
25 Mar 2020
COVID-19: Health Canada Simplifies Regulatory Requirements For COVID-19-Related Products
Article
10 Mar 2020
COVID-19: Health Canada Issues Bulletin Confirming Obligations Of DEL Holders
Article
23 Dec 2019
Ontario Government Introduces Legislation Proposing Significant Amendments To The Class Proceedings Act
Article
19 Dec 2019
Ontario Reduces Restrictions On Ordinary Commercial Term Benefits And Private Label Products
Article
11 Mar 2019
Ontario Introduces Legislation To Change Healthcare Administration
Article
29 May 2018
ONCA Upholds Dismissal Of Summary Judgment In Lansoprazole s. 8 Case
Article
12 Mar 2018
Reforming Class Actions In Ontario – Your Input Please!
Article
21 Mar 2017
Pharma In Brief - Ontario Superior Court Of Justice Dismisses Motion For Summary Judgment In Lansoprazole Section 8 Damages Action
Article
22 Jul 2016
New Updates To Consumer Product Regulations In Force
Article
02 Feb 2016
Consumer Claims Under Canada's Patent Regime Foreclosed
Article
21 Dec 2015
Pharma In Brief - British Columbia Court Of Appeal Finds That Consumer Claims Based On Alleged Breaches Of The Canadian Patent Regime Are Prohibited